Methamphetamines clinical trials at UCSF

2 in progress, 1 open to eligible people

Methamphetamines are powerful stimulants that can lead to addiction. UCSF is researching how ketamine injections paired with therapy might help individuals with methamphetamine use disorder and HIV. The study focuses on using medical treatment alongside psychotherapy.

Showing trials for

  • Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

    open to eligible people ages 18-69

    The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer are: - Do publicly insured patients find ketamine-assisted psychotherapy feasible and acceptable as a potential treatment for MeUD? - Is IM ketamine safe and tolerable among patients with MeUD? Participants will: - Receive 3 monitored doses of IM ketamine - Have 3 preparation and 4 integration psychotherapy visits - Report their daily amounts of methamphetamine used prior to, during, and up to 3 months following the intervention

    San Francicso, California 5332921

  • CHAMPION: Combining HIV And Meth Prevention and Treatment Interventions Optimized for HIV-Negative MSM

    Sorry, not yet accepting patients

    The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: - To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. - To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.

    San Francisco 5391959, California 5332921

Our lead scientists for Methamphetamines research studies include .

Last updated: